Scholarlink

<p>Inflammation is commonly recognized as a significant contributor to the emergence and pathogenesis of numerous diseases. Nanoformulations loaded with therapeutic entities provide a promising strategy against inflammation-related illnesses by enhancing the effectiveness, bioavailability, and targeted administration of both natural and conventional medications. Dodecyl gallate (DG) is well documented for its biological potential. Earlier, we described the synthesis and in vitro anti-proliferative potential of the liposomal nanoformulation of DG (Nano-DG). This study focuses on the drug release profile and explores its anti-inflammatory effects pre-clinically, along with the evaluation of its potential toxicity in Wistar rats. At p<sup>H</sup> 6.8 and room temperature, an initial 15% release of DG was observed at 1&#xa0;h, followed by sustained release over 48&#xa0;h, reaching a maximum cumulative release of 81%. Nano-DG significantly inhibited induced intracellular ROS and NO generated from phagocytic cells and effectively reduced rats’ hind paw edema at all tested doses (5, 10, and 20&#xa0;mg/kg), particularly at 48&#xa0;h. No significant alterations in hematological, serological, and biochemical profiles were observed in acute toxicological studies. Histopathological examination showed no tissue damage. The Nano-DG retained its biological potential, displaying superior therapeutic efficacy compared to its free form against inflammatory illnesses, which supports its potential as a safe and effective therapeutic agent.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pre-clinical Assessment of Nanoliposome Encapsulated Dodecyl Gallate for the Treatment of Inflammatory Diseases

  • 期刊论文

  • 发表日期：

    2026年3月24日

查看全文
  • Sidrah Shams,
  • Farwa Naqvi,
  • Syeda Farah Shah,
  • Tooba Jabri,
  • Abdul Jabbar,
  • Muhammad Raza Shah,
  • Shaheen Faizi,
  • Almas Jabeen

摘要

Inflammation is commonly recognized as a significant contributor to the emergence and pathogenesis of numerous diseases. Nanoformulations loaded with therapeutic entities provide a promising strategy against inflammation-related illnesses by enhancing the effectiveness, bioavailability, and targeted administration of both natural and conventional medications. Dodecyl gallate (DG) is well documented for its biological potential. Earlier, we described the synthesis and in vitro anti-proliferative potential of the liposomal nanoformulation of DG (Nano-DG). This study focuses on the drug release profile and explores its anti-inflammatory effects pre-clinically, along with the evaluation of its potential toxicity in Wistar rats. At pH 6.8 and room temperature, an initial 15% release of DG was observed at 1 h, followed by sustained release over 48 h, reaching a maximum cumulative release of 81%. Nano-DG significantly inhibited induced intracellular ROS and NO generated from phagocytic cells and effectively reduced rats’ hind paw edema at all tested doses (5, 10, and 20 mg/kg), particularly at 48 h. No significant alterations in hematological, serological, and biochemical profiles were observed in acute toxicological studies. Histopathological examination showed no tissue damage. The Nano-DG retained its biological potential, displaying superior therapeutic efficacy compared to its free form against inflammatory illnesses, which supports its potential as a safe and effective therapeutic agent.

Graphical Abstract